Drug Profile
Research programme: ischaemic heart disorders therapeutics - Pierre Fabre
Alternative Names: 16916; F16916Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in France
- 31 Dec 2007 Preclinical trials in Ischaemic heart disorders in France (unspecified route)